Acute Pain Clinical Trial
Official title:
An Evaluation of the Efficacy and Safety of Tapentadol Oral Solution in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Subjects Aged From Birth to Less Than 18 Years Old
The purpose of the study was to evaluate the efficacy of tapentadol oral solution, based on the total amount of supplemental opioid analgesic used over 12 hours or 24 hours after initiation of investigational medicinal product (IMP) in children and adolescents who had undergone surgery that would produce moderate to severe pain during opioid treatment.
The supplemental opioid medication reflecting the standard of care was available as patient-
or nurse-controlled intravenous (i.v.) morphine or hydromorphone. This supplemental opioid
analgesic medication (SOAM) was given to control pain, as needed, in both the treatment and
placebo groups.
Children and adolescents 6 months and older were dosed with a dose regimen of 1.25 mg/kg body
weight for the first 24 hours of treatment. 24 hours after the start of study medication (and
based on clinical judgment), a dose reduction to 1.0 mg/kg was allowed.
Participants 30 days to less than 6 months old were dosed with a regimen of 0.5 mg/kg for the
first 24 hours of treatment. The dose of IMP could be reduced after 24 hours to 0.3 mg/kg (if
there was a reduced need for analgesia according to the investigator's judgment).
Participants aged from birth to less than 30 days old were dosed with a regimen of 0.1 mg/kg
for the first 24 hours of treatment. The dose of the IMP could be reduced after 24 hours to
0.075 mg/kg (if there was a reduced need for analgesia according to the investigator's
judgment).
The decision to maintain or alter the dose based on the effectiveness of the analgesia (pain
killer) and the adverse event profile observed in each participant over the first 24-hour
dosing period was made based on the investigator's judgment.
In exceptional cases, if a participant had unbearable pain despite using nurse-controlled
analgesia (NCA) or patient-controlled analgesia (PCA), an additional bolus (defined as a
clinician bolus) of morphine or hydromorphone could have been administered. The clinician
bolus could have been given either using the NCA/PCA pump system or by an intravenous bolus
injection. The opioid given as a clinician bolus or if the NCA/PCA intravenous line failed,
had to be the same opioid used in the NCA/PCA pump system.
Dosing with IMP was stopped if:
- A switch to exclusively oral opioid analgesic medication was indicated according to the
local standard of care.
- Opioid analgesic medication was no longer needed.
- IMP had been administered for 72 hours.
Safety evaluations included assessment of adverse events, physical examination, vital signs,
laboratory parameters, electrocardiogram, oxygen saturation, and, only for children older
than 6 years of age, a scale to assess suicidal ideation (Columbia Suicide Severity Rating
Scale [C-SSRS]). The maximum study duration for each participant was 42 days.
The evaluation of the safety and efficacy data was performed by age groups as aligned with
European and United States agencies. Within the tapentadol treatment group, no analysis by
tapentadol dose was conducted. Results for participants aged 2 years to <18 years were
provided to the Pediatric Committee of the European Medicines Agency (EU PDCO) before
recruitment of the children less than 6-month old required for the US Food and Drug
Administration [FDA] analysis was completed. Participants from birth to <2 years old were
analyzed separately for the US FDA only and not included in the analysis of the population
aged from 2 years to <18 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04484610 -
Appropriate Opioid Quantities for Acute Pain - Pharmacist Study
|
Phase 4 | |
Recruiting |
NCT05054179 -
Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04548635 -
VR for Burn Dressing Changes at Home
|
Phase 2/Phase 3 | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT03825549 -
A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing
|
N/A | |
Completed |
NCT05995912 -
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
|
Phase 2 | |
Recruiting |
NCT05589246 -
Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure
|
N/A | |
Recruiting |
NCT05572190 -
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
|
Phase 1 | |
Terminated |
NCT04716413 -
Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment
|
Phase 4 | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Not yet recruiting |
NCT06317844 -
Examination of Psychological and Physiological Pathways Linking Gratitude and Pain
|
N/A | |
Withdrawn |
NCT02957097 -
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures
|
Phase 4 | |
Completed |
NCT02565342 -
Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery
|
Phase 4 | |
Terminated |
NCT02599870 -
Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures
|
N/A | |
Completed |
NCT02380989 -
Integrative Ayurveda Healing Relieves Minor Sports Injury Pain
|
Phase 2 | |
Completed |
NCT02984098 -
40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose
|
Phase 4 | |
Completed |
NCT02489630 -
Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department
|
Phase 4 | |
Completed |
NCT03107338 -
Preventive Treatment of Pain After Dental Implant Surgery
|
Phase 4 | |
Completed |
NCT02817477 -
Intranasal Ketamine for Acute Traumatic Pain
|
Phase 4 |